FDA-Ready Guide – Labeling Standards for Clinical Samples

Published on 22/12/2025

FDA-Ready Guide – Labeling Standards for Clinical Samples

Table of Contents

Introduction: Why Proper Sample Labeling is Critical

Accurate labeling of clinical samples is essential for ensuring traceability, subject confidentiality, and regulatory compliance. Regulatory authorities such as the FDA and EMA routinely cite mislabeling, incomplete identifiers, or illegible sample labels as significant compliance risks. The ICH E6(R2) and FDA 21 CFR Part 58 both emphasize the need for unique identification and traceable sample chains.

This article presents FDA- and EMA-compliant standards for clinical sample labeling, with a focus on SOP design, risk mitigation, and CAPA implementation for labeling errors.

Regulatory Expectations for Clinical Sample Labels

According to FDA and EMA inspection manuals, clinical sample labels must meet the following minimum requirements:

Unique Subject ID (without patient name)
Visit number or collection timepoint
Date and time of collection (if required by protocol)
Sample type (e.g., serum, plasma, urine)
Study code or protocol number
Blinding status (if applicable)

Labels must be affixed prior to sample shipment and verified for legibility, adhesion, and completeness. Illegible or damaged labels are considered critical deviations by inspectors.

Types of Labels Used in Clinical Trials

Depending on the study design and central lab requirements, the following types of labels are used:

Pre-printed Barcode Labels: Generated by central lab or sponsor system
Manual Labels: Hand-written using permanent marker, often for backup or unexpected samples
Electronic Sample Labels (eLabels): Dynamic labels generated by ePRO or EDC-integrated systems
Cryogenic Labels: For -80°C or liquid nitrogen storage, resistant to condensation and freezing

Common Audit Findings Related to Sample Labeling

Duplicate Subject IDs on different samples
Illegible handwriting on manually labeled tubes
Use of expired label stock (ink fading or detaching)
Inconsistency in visit labeling (e.g., “Visit 2” vs “V2”)
Misaligned label text or barcodes not scannable

These findings often result in sample rejection by central labs and compromise data integrity.

Best Practices for Sample Labeling SOPs

A robust labeling SOP should include:

Label format templates with defined fields
Labeling process workflow (who, when, where)
Pre- and post-labeling verification steps
Storage and disposal of unused labels
Contingency plan for re-labeling due to damage or error

Table: Clinical Sample Labeling Checklist

Label Element	Required?	Notes
Unique Subject ID	Yes	No names; follow site ID conventions
Visit Number	Yes	Match protocol nomenclature
Sample Type	Yes	E.g., Serum, Plasma, Urine
Date/Time of Collection	Conditional	As per protocol
Barcode or QR Code	Recommended	Ensure scanner compatibility

CAPA Strategy for Labeling Errors

Labeling errors must be documented, investigated, and corrected via CAPA. A sample CAPA flow includes:

Deviation Report: Document the error (e.g., sample received without subject ID)
Root Cause: Identify if it’s due to lack of training, SOP gap, or equipment
Action: Retrain staff, revise SOP, or use pre-printed labels only
Verification: Audit next 20 samples for compliance

Training and Inspection Readiness

Site staff must be trained specifically on:

How to interpret and apply label templates
Use of barcode printing tools and label applicators
Maintaining label inventory and expiry tracking
Documentation of re-labeled samples with justification

Training logs, labeling SOPs, and sample labeling QC records should be readily available during site inspections.

External Registry Reference

Trials with detailed biospecimen labeling methods are searchable on Be Part of Research – NIHR UK Clinical Studies Registry.

Conclusion

Clinical sample labeling is more than a clerical task—it is a foundational compliance requirement. By following FDA- and EMA-aligned SOPs, using validated labeling systems, training staff adequately, and applying CAPA for any deviations, sponsors can ensure both biospecimen traceability and inspection readiness. Labeling errors may seem minor, but their consequences can undermine entire datasets—making rigorous processes essential.